Padhi Bijaya K, Gupta Parul Chawla, Al Kaabi Nawal A, Al-Subaie Maha F, Alrasheed Hayam A, Sulaiman Tarek, Rabaan Ali A, Khatib Mahalaqua Nazli, Gaidhane Shilpa, Zahiruddin Quazi Syed, Dziedzic Arkadiusz, Satapathy Prakasini, Fraj Najat J, Aldrazi Fatimah A, Kukreti Neelima, Rustagi Sarvesh, Abu Serhan Hashem
Department of Community Medicine and School of Public Health, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Department of Ophthalmology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Ophthalmic Epidemiol. 2025 Feb;32(1):112-120. doi: 10.1080/09286586.2024.2343714. Epub 2024 May 6.
In the wake of the COVID-19 pandemic, vaccines have been pivotal in curbing disease spread and severity. However, concerns over post-vaccination adverse events, including uveitis, an inflammatory ocular condition, have been noted. This systematic review and meta-analysis aimed to evaluate the incidence and association of uveitis following COVID-19 vaccination.
A literature search was performed across several databases on October 21, 2023. Human studies examining the incidence of uveitis post-COVID-19 vaccination were included. The Newcastle-Ottawa Scale was used for quality appraisal of the included studies. Meta-analysis was performed to assess the overall incidence of uveitis and the relative risk of developing the condition post-vaccination. All statistical analyses were performed using R software version 4.3.
Six studies involving over 2 billion vaccine doses were included. The overall incidence of uveitis was 0.016% (95% CI: 0.010 to 0.026). No significant association was found between vaccination and the onset of uveitis (Relative Risk: 1.45 (95% CI: 0.82 to 2.57, = 0.12) from four studies. The evidence quality was rated very low due to the limited number of studies and imprecision.
This analysis indicates a low incidence of uveitis following COVID-19 vaccination and no significant association with the vaccine. The findings are constrained by the small number of studies and low certainty of evidence, underscoring the need for further research. Comprehensive and longitudinal studies are necessary to confirm these findings and reinforce public confidence in COVID-19 vaccination programs.
在新冠疫情之后，疫苗在控制疾病传播和严重程度方面发挥了关键作用。然而，人们已注意到对疫苗接种后不良事件的担忧，包括葡萄膜炎（一种眼部炎症性疾病）。本系统评价和荟萃分析旨在评估新冠疫苗接种后葡萄膜炎的发病率及相关性。
于2023年10月21日在多个数据库进行文献检索。纳入研究新冠疫苗接种后葡萄膜炎发病率的人体研究。采用纽卡斯尔 - 渥太华量表对纳入研究进行质量评估。进行荟萃分析以评估葡萄膜炎的总体发病率以及接种疫苗后发生该病的相对风险。所有统计分析均使用R软件版本4.3进行。
纳入六项涉及超过20亿剂疫苗的研究。葡萄膜炎的总体发病率为0.016%（95%置信区间：0.010至0.026）。四项研究未发现疫苗接种与葡萄膜炎发病之间存在显著关联（相对风险：1.45（95%置信区间：0.82至2.57，P = 0.12）。由于研究数量有限和结果不精确，证据质量被评为极低。
该分析表明新冠疫苗接种后葡萄膜炎发病率较低，且与疫苗无显著关联。这些发现受到研究数量少和证据确定性低的限制，凸显了进一步研究的必要性。需要进行全面的纵向研究以证实这些发现并增强公众对新冠疫苗接种计划的信心。
